Clinical trials
Tomography clinical trials
Below are recruiting tomography clinical trials, each written for real people, not researchers. We’re tracking 839 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06236685Enrolling by invitation
Optimizing ventilation monitoring with advanced techniques
This trial tests a new way to monitor breathing for people on a ventilator during surgery or in intensive care. It aims to improve care by combining advanced monitoring methods.
PragueAges 18 years+ - NCT06249282RecruitingPhase 1
Carfilzomib and sotorasib for KRAS G12C lung cancer
This trial tests a combination of two drugs: carfilzomib and sotorasib, for people with a specific type of advanced lung cancer (KRAS G12C mutation) who have already tried a KRAS-targeting drug that stopped working. The goal is to see if this new combination can shrink tumors or slow the cancer.
Duarte, CaliforniaAges 18 years+ - NCT06223542RecruitingPhase 1
TAK-243 for advanced cancers that haven't responded to other treatments
This trial tests a new drug called TAK-243 for people with advanced cancers (solid tumors or lymphomas) that have not responded to other treatments. It aims to see if the drug is safe and how well it works.
Bethesda, MarylandAges 18 years+ - NCT06227754Recruiting
OCT vs. angiography for heart attack treatment
This trial compares two ways to guide treatment during a heart attack: using a special camera (OCT) inside the artery or standard X-ray (angiography). It aims to see which method leads to better results for patients.
Daegu, DaeguAges 19 years+ - NCT06225427RecruitingPhase 1
Gilteritinib for advanced ALK-positive lung cancer
This trial tests a drug called gilteritinib for people with a specific genetic type of lung cancer (ALK-positive) that has spread and has been treated before. You may be eligible if you have already tried at least one targeted therapy, and your cancer is still growing.
Los Angeles, CaliforniaAges 18 years+ - NCT06224673RecruitingPhase 2
Testing ARX788 for HER2-low advanced breast cancer
This trial tests a new drug, ARX788, for people with HER2-low breast cancer that has spread or cannot be removed by surgery. The goal is to see if ARX788 helps shrink or control the cancer.
San Francisco, CaliforniaAges 18 years+ - NCT06203600RecruitingPhase 2/Phase 3
Nivolumab plus standard treatment for advanced stomach or esophageal cancer
This trial tests whether adding the immunotherapy drug nivolumab to standard treatment works better for advanced stomach or esophageal cancer. It is for people whose cancer has already progressed after a first round of chemo plus immunotherapy.
Little Rock, ArkansasAges 18 years+ - NCT06182683Recruiting
OCT-Guided vs. FFR-Guided Stent Placement in Heart Disease
This trial compares two imaging and pressure tests used during stent placement to see which helps improve blood flow better in people with chest pain or a recent heart attack.
SeoulAges 19 years+ - NCT06199713Recruiting
Melanoma trial tracking treatment response with PET scans and blood tests
This study is looking at whether a special PET scan (FDG PET/CT) and a blood test that measures ctDNA (cancer DNA in the blood) can help predict how well immune checkpoint inhibitors work in people with advanced melanoma. If you are planning to get treatment with immunotherapy drugs like ipilimumab, nivolumab, or pembrolizumab, you may be able to join.
Madison, WisconsinAges 18 years+ - NCT03713268Recruiting
Using a scan to guide eye surgery in real time
This trial tests whether a special eye scan (OCT) can help guide eye surgery during the operation. It may improve how surgeons see and target the exact eye structures they need to treat.
Durham, North CarolinaAges 4 weeks+ - NCT05558059Recruiting
Scan blood vessels in preemie babies’ eyes with special imaging
This study uses pictures to map the tiny blood vessels in an infant’s retina (the back of the eye). It may help researchers better understand how eye blood vessel growth happens in premature babies who need screening for ROP (retinopathy of prematurity).
Durham, North CarolinaAges Up to 2 months - NCT06167642Enrolling by invitation
Retinal health and nerve markers in MS patients taking ofatumumab
This study looks at how ofatumumab (Kesimpta) affects the back of the eye (retina) and certain nerve proteins in the blood in people with relapsing multiple sclerosis. It may help doctors understand how well the medication is protecting the eyes and nerves.
Baltimore, MarylandAges 18–70 - NCT06170541Recruiting
Comparing heart artery scans for coronary disease
This study tests whether a newer CT scan method can better detect coronary heart disease. You may qualify if your doctor referred you for a heart CT scan.
Baltimore, MarylandAges 21–85 - NCT05518617Recruiting
Imaging study for inherited Parkinson’s using PET, SPECT, and spinal fluid
This trial tests how well special brain scans (PET/SPECT) and spinal fluid tests can show changes in people with inherited (genetic) Parkinson’s. It may help researchers understand what’s happening in the brain and improve how these conditions are measured.
Exeter, DevonAges 25–80 - NCT06132685RecruitingPhase 2
Dexamethasone dosing after brain tumor surgery
This trial tests how to best use dexamethasone (a steroid) after brain tumor surgery to help recovery and reduce swelling. It looks at different dosing schedules for patients with common brain tumors.
Atlanta, GeorgiaAges 18 years+ - NCT06126276RecruitingPhase 2
Testing neratinib with or without palbociclib for HER2+ solid tumors
This trial tests two targeted drugs—neratinib alone or with palbociclib—for people with HER2-positive solid tumors (other than breast cancer) that have returned or not gone away. The goal is to see if blocking HER2 and CDK4/6 can shrink or slow the tumor.
Birmingham, AlabamaAges 18 years+ - NCT06116682RecruitingPhase 2
Targeted treatment for MET-positive advanced lung cancer
This trial tests a targeted therapy for people with advanced non-small cell lung cancer whose tumors have extra copies of the MET gene. It's for those whose cancer has progressed after at least one prior treatment.
Jonesboro, ArkansasAges 18 years+ - NCT06104618RecruitingPhase 2
Enfortumab vedotin for advanced penile cancer
This trial tests a drug called enfortumab vedotin for people with advanced penile cancer (squamous cell carcinoma) that has spread or cannot be surgically removed. The goal is to see if the drug can shrink tumors or slow the cancer's growth.
Phoenix, ArizonaAges 18 years+ - NCT06128070RecruitingPhase 2
Preventing GVHD after stem cell transplant for leukemia
This trial tests adding ruxolitinib to standard drugs (tacrolimus and methotrexate) to prevent graft-versus-host disease in children and young adults undergoing a stem cell transplant for acute leukemia or myelodysplastic syndrome. The goal is to lower the risk of GVHD and improve transplant outcomes.
Duarte, CaliforniaAges 2–22 - NCT06102902RecruitingPhase 1
New drug added to chemotherapy for BRAF-mutated colorectal cancer
This trial combines a new drug called ZEN003694 with two standard chemotherapy drugs (cetuximab and encorafenib) to see if it can help people with a specific type of colorectal cancer that has the BRAF V600E mutation. This mutation makes the cancer grow, and the new drug targets it, potentially making the treatment more effective.
Costa Mesa, CaliforniaAges 18 years+ - NCT06086704RecruitingPhase 2
PET/MRI scan for PR-positive breast cancer before surgery
This trial tests a new PET/MRI scan (using a special tracer called 18F-FFNP) to see how it images progesterone-receptor-positive breast cancer before surgery. You would get the scan and then have your planned surgery.
Madison, WisconsinAges 18 years+ - NCT06083064Recruiting
Smarter imaging choices for suspected appendicitis
This trial tests whether using a step-by-step approach to decide which imaging test (CT scan or ultrasound) is best for people with suspected appendicitis, instead of routinely giving everyone a CT scan or ultrasound. It may help avoid unnecessary scans.
EspooAges 18 years+ - NCT05717153RecruitingEarly Phase 1
Test drugs through the tumor to study brain tumor metabolism
This early-phase study tests two drugs (DFMO and AMXT 1501) given directly into the tumor to see how they affect tumor biology and metabolism. Researchers may learn whether this approach could be safer and helpful for people with diffuse or high-grade glioma.
Rochester, MinnesotaAges 18 years+ - NCT05943496RecruitingPhase 1
Tafasitamab plus acalabrutinib and obinutuzumab for untreated CLL/SLL
This Phase 1 study tests a new combination of medicines to treat people whose chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) has not been treated before and needs therapy. It aims to shrink the disease and control it safely in this early testing stage.
Portland, OregonAges 18 years+
Hear when a new Tomography trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for tomography?
- Yes. Clin2 currently lists 839 recruiting tomography studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a tomography trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a tomography trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.